Blue Bell Private Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-10
Closed -$3K 843
2022
Q2
$3K Hold
10
﹤0.01% 616
2022
Q1
$3K Hold
10
﹤0.01% 654
2021
Q4
$2K Buy
+10
New +$1.95K ﹤0.01% 719

Other funds holding VRTX

Blue Bell Private Wealth Management's VRTX Position: Q3 2022 in Review

Blue Bell Private Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2022, closing a stake of 10 shares — an estimated $3K sold.

Blue Bell Private Wealth Management first reported a position in VRTX in Q4 2021 and held it in 3 quarters. The position peaked at $3K in Q2 2022. 1,124 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.

  • Blue Bell Private Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Blue Bell Private Wealth Management sold 10 Vertex Pharmaceuticals shares in Q3 2022, an estimated $3K.
  • Blue Bell Private Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • Blue Bell Private Wealth Management's Vertex Pharmaceuticals position peaked at $3K in Q2 2022.
  • 1,124 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.

Based on Blue Bell Private Wealth Management's 13F filing for Q3 2022, filed 9 Nov 2022.